- Acumen Powered by Robins Kaplan LLP®
- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Entertainment and Media Litigation
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Fiduciary Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
May 13, 2024Robins Kaplan, Robert Bennett Recognized in Elite Trial Lawyers Awards
-
April 29, 2024Robins Kaplan Mourns Death of New York Associate Waleed Abbasi
-
April 29, 2024Robins Kaplan Secures $7.75 Million Verdict in Aerosol Dust Remover Abuse Case
-
May 20, 2024The Present and Future of DEI
-
May 23, 202414th Annual Disability Justice Seminar
-
June 10-11, 20242024 Probate and Trust Law Section Conference
-
May 2024Q&A with Anthony Froio
-
April 30, 2024A World Without Non-Competes: Protecting Confidential Information and Trade Secrets Following the FTC's Ban
-
First QuarterGENERICally Speaking: A Hatch-Waxman Litigation Bulletin
-
September 16, 2022Uber Company Systems Compromised by Widespread Cyber Hack
-
September 15, 2022US Averts Rail Workers Strike With Last-Minute Tentative Deal
-
September 14, 2022Hotter-Than-Expected August Inflation Prompts Massive Wall Street Selloff
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
UCB, Inc. v. Mylan Techs. Inc.
Neupro® (rotigotine)
March 8, 2024
Case Name: UCB, Inc. v. Mylan Techs. Inc., Civ. No. 22-cv-216 (D. Vt. Mar. 8, 2024) (Reiss, J.)
Drug Product and Patent(s)-in-Suit: Neupro® (rotigotine); U.S. Patents Nos. 8,246,979 (“the ’979 patent”) and 8,246,980 (“the ’980 patent”)
Nature of the Case and Issue(s) Presented: Neupro is a transdermal patch indicated for the treatment of Parkinson’s’ disease and restless leg syndrome. On March 24, 2017, UCB filed a complaint in the District of Delaware, alleging that Mylan’s ANDA infringed five patents, including the ’979 patent and the ’980 patent.
On July 16, 2019, UCB filed an infringement action in the District of Vermont alleging infringement of two pop-up, Neupro patents. The District of Delaware action was thereafter transferred to Vermont. The parties attempted to negotiate a resolution, but reached an impasse as UCB was only willing to issue a covenant not to sue on the drug products then described in Mylan’s ANDA, whereas Mylan wanted the covenant to apply to its current ANDA product “including any amendments and/or supplements thereto.” The parties eventually filed a stipulation of dismissal with only UCB’s language on May 13, 2020.
On October 27, 2022, Mylan submitted a major amendment to its ANDA and sent UCB notice with a paragraph IV certification. The paragraph IV certification alleged non-infringement because the changes to the ANDA did not “alter the infringement analysis” and thus, according to Mylan, the covenant not to sue still applied. In response, UCB filed suit and obtained a 30-month stay of approval of Mylan’s ANDA. Mylan moved for partial summary judgment, arguing that UCB breached the covenant not to sue and sought a declaration that it did not infringe the ’979 and ’980 patents.
Why UCB Prevailed: Mylan first argued that the covenant not to sue covered modifications and supplements to the product that was the subject to the parties’ prior settlement. The court disagreed and found that the covenant not to sue applied only to Mylan’s ANDA product as described as of the date of settlement on May 27, 2020.
Mylan next argued that the covenant not to sue applied unless the changes to the ANDA “altered the infringement analysis with respect to the ’979 and ’980 patents.” The court agreed and found that because UCB was both the drafter of the stipulation and because this language created a condition subsequent to the covenant not to sue, then UCB possessed the burden of proving that Mylan’s ANDA product in fact had changed. Thereafter, the court found that there was a fact issue regarding whether Mylan changed its ANDA product in such a way that altered the court’s infringement analysis. As a result, it denied Mylan’s motion for summary judgment.
Related Publications
Related News
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.